IntermediateEducational map · not a treatment protocol

Anti-Aging & Cellular Longevity

Educational map of GH secretagogues, pineal cytogens, and dermal peptides used in longevity folklore. Telomerase and “youthful gene expression” are not a US anti-aging indication.

Duration

3-6 months (cyclical)

First reports

4-8 weeks

SKUs on this map

7

1Overview

This page maps reconstitution math and folklore stacks. Secretagogues can raise GH/IGF-1 in short studies. Epitalon telomerase claims are one-lab. Khavinson mortality follow-ups used Epithalamin plus Thymalin in elderly Russian cohorts, not this US research-chem mix. Nobody should treat this as a biological-age reversal protocol.

Ideal Candidates

✓Adults mapping GH-secretagogue and pineal-cytogen SKUs used in longevity folklore
✓People comparing pulsatile GHRH/GHRP math to somatropin
✓Readers who need GHK-Cu gene-expression marketing named as marketing, not an NDA

Contraindications

✕Active cancer or history of cancer (due to growth-promoting pathways)
✕Pregnant or breastfeeding women
✕Uncontrolled systemic autoimmune conditions

2The Science

This page maps SKUs that show up in longevity folklore: pulsatile GHRH/GHRP secretagogues, the pineal tetrapeptide Epitalon, GHK-Cu, and NAD+ as a cofactor talking point. Telomere shortening, GH decline, and NAD-percent charts are lecture-slide frames, not a four-axis US anti-aging indication. Nothing here is a biological-age reversal protocol.

Biological Rationale

"GH falls ~14% per decade" and "NAD+ drops ~50% from 40–60" are talking points, not reconstitution math. Telomere bp/year figures are population cytogenetics, not an Epitalon dosing table. This stack does not restore youthful GH output or a sirtuin program.


3Clinical Evidence

Moderate Evidence

Key Findings

1

Epithalon induced telomerase activity and telomere elongation in human fibroblasts in that lab’s in-vitro system. That is not a human lifespan trial.

Khavinson et al., 2003DOI ↗

2

Epithalamin plus Thymalin mortality follow-ups were elderly Russian cohorts on those extracts, not this US research-chem mix.

St. Petersburg Institute of Bioregulation and Gerontology

3

GHK-Cu microarray papers report thousands of expression changes. That is an array, not a wrinkle RCT or a "youthful genome" reset.

Pickart et al., skin biology studies

4

GHRH/GHRP secretagogues can raise GH/IGF-1 in short human studies. That is not somatropin and not an anti-aging indication.

Phase 1/2 secretagogue literature

5

Oral NAD precursor trials (NR/NMN) are a different SKU from injectable NAD+. Neither is a sirtuin-restoration protocol on this page.

NAD precursor literature, not this vial

Study Limitations

  • ⚠Epithalon data primarily from one group (Khavinson); independent replication limited
  • ⚠CJC-1295/Ipamorelin not FDA-approved; data from off-label clinical use
  • ⚠Long-term telomerase activation safety requires further study (theoretical cancer risk)
  • ⚠NAD+ delivery route significantly affects bioavailability; optimal method debated
  • ⚠GHK-Cu injectable human data limited vs. extensive topical research

4The Peptide Stack

EP

Khavinson tetrapeptide (AEDG). Telomerase and fibroblast papers exist from that group. Not a US anti-aging NDA. Independent replication is thin.

Mechanism: Synthetic tetrapeptide (Ala-Glu-Asp-Gly). hTERT papers exist from the Khavinson group. Melatonin-restoration language is that literature, not a jet-lag NDA.

Half-life: ~2-4 hours (estimated)Dose range: 5-10 mg/day
CJ

CJC-1295 (no DAC)

View Profile →

GHRH analog used for pulsatile GH. No-DAC vs DAC is a different week. Not somatropin.

Mechanism: Binds GHRH receptors on somatotroph cells. No-DAC half-life is short (~30 min), so any GH pulse is brief. That is PK, not a proven “preserves natural pulsatility” outcome.

Half-life: ~30 minutesDose range: 100-300 mcg/injection
IP

Selective ghrelin receptor (GHS-R1a) agonist used with a GHRH analog. Cortisol/prolactin sparing vs GHRP-6 is the usual selling point, not a cleanliness ranking.

Mechanism: Binds GHS-R1a on the pituitary for immediate robust GH pulses. High selectivity minimizes side effects vs. GHRP-6/GHRP-2.

Half-life: ~2 hoursDose range: 100-300 mcg/injection
GH

Copper tripeptide with Pickart microarray papers. "4,000+ genes" is expression-array marketing, not a wrinkle RCT or a US reconstruction indication.

Mechanism: Copper-binding tripeptide. Collagen and microarray papers exist. Epigenetic-switch language is marketing for those arrays, not a reconstruction indication.

Half-life: ~1-2 hours (estimated)Dose range: 1-3 mg/day (SC) or topical
NA

NAD+ is a cofactor. IV or research vials are not a sirtuin-restoration NDA. Percent-decline slides are not a protocol.

Mechanism: Nicotinamide adenine dinucleotide is a cofactor for sirtuins and PARP. Replenishing a vial is not restoring a sirtuin program.

Half-life: ~45 minutes (IV)Dose range: 50-250 mg (SubQ) or 250-1000 mg (IV)
NM

Oral NAD+ precursor identity. Not a peptide vial and not interchangeable with injectable NAD+ folklore on this hub.

Half-life: Oral precursor pharmacokinetics (not a peptide t½)Dose range: Oral NAD+ precursor - not a peptide vial
UR

Urolithin A

View Profile →

Mitophagy metabolite sold as an oral longevity ingredient. Not MOTS-c, not SS-31, not reconstitution math.

Half-life: Oral metabolite pharmacokinetics (not a peptide t½)Dose range: Oral supplement / researched doses - not a peptide vial

5Protocol Tiers

Foundational Baseline (GH Optimization)

GHRH analog plus ipamorelin as they show up in clinic folklore. Pulsatile vs DAC is a different SKU question. Not somatropin.

Duration
8-12 weeks
Frequency: Daily (5 days on, 2 days off recommended to prevent desensitization)
Timing: 30-45 minutes before bed on an empty stomach
Ipamorelin100-200 mcg
Timing: Administered in the same syringe as CJC-1295 prior to bed
Clinical Note: Fasting 2-3 hours before injection minimizes insulin interference with the GH pulse.

The Rejuvenation Stack

Short Epitalon bursts plus GHK-Cu as they are sold together in longevity folklore. Not a senescence or DNA-repair indication.

Duration
10-20 day "bursts"
Frequency: Daily during burst phases
Epitalon5-10 mg
Timing: Morning
Clinical Note: Typically run in short bursts 2-3 times per year.
GHK-Cu1.5-2 mg
Timing: Any time of day
Clinical Note: Can be run continuously or overlapping with GH optimization.

6Lifestyle Integration

Lifestyle notes that travel with these SKUs. Not a prescription and not required for the math to be valid.

Training

Zone 2 and lifting are training. They are not required to "activate" a peptide.

Nutrition

Protein and energy still drive composition. Fasting is a GH-pulse talking point, not a peptide protocol.

Sleep

GH pulses cluster in slow-wave sleep. Bedtime secretagogue timing is folklore timing, not a sleep clinic.

Stress Management

Cortisol vs GH is physiology 101. Breathwork is not a telomere drug.

7Timeline & Expectations

Weeks 1-3

What You'll NoticeDeeper sleep is the usual GH-pulse report. That is not proof of telomere repair.
What's Happening BiologicallyExogenous peptides are increasing the amplitude of nightly GH pulses, beginning to trigger systemic cellular signaling shifts.

Weeks 4-8

What You'll NoticeFaster workout recovery is commonly reported with GH secretagogues. Skin changes, if any, are not a reconstruction indication.
What's Happening BiologicallyIGF-1 reaches new steady-state plateaus; GHK-Cu begins actively modulating genomic expression toward repair states.

Months 3-6

What You'll NoticeBody recomposition still needs protein and training. "Looking younger" is not a trial endpoint on this stack.
What's Happening BiologicallyNo validated "biological age" endpoint on this mix. Epitalon bursts do not equal proven telomere maintenance in US research-chem use.

8Monitoring & Safety

Key Metrics to Track

Serum IGF-1Monitor every 8-12 weeks; target the upper quartile for your age group, avoiding supraphysiological levels.
hs-CRP (Inflammation)Should remain <1.0 mg/L as the anti-inflammatory effects of the protocol compound.

Troubleshooting

Water retention or minor joint aching
Possible Causes
  • Normal initial physiological adaptation to higher GH
  • Dose is too aggressive
Solutions
  • Reduce dose by 30%
  • Ensure adequate hydration and electrolyte balance
  • Typically resolves naturally in 2 weeks
Disrupted sleep initially
Possible Causes
  • Dosing too close to bedtime
  • Over-amplified GH pulse causing vivid dreaming
Solutions
  • Shift administration to 60-90 minutes prior to bed rather than immediately before

9Further Reading

Dive deeper into the individual peptides and methodologies behind this protocol.